New
Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
SBIO ETF · Invesco NASDAQ Biotech UCITS ETF
The SBIO Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: NASDAQ Biotechnology Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). The dividend policy is capitalization.
Last update Yesterday at 7:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.+5.51%
Last price
$62.03
1M perf.
-0.08%
1M flows
+€12M
AuM
€358M
TER
0.4%
Rating
ESG Consensus®
SBIO
$62.03
Performance & flows
Segment for quartile rank
March 11, 2026 → June 11, 2026
Create a free account to view the flows graph
SBIO
$61.70
+0.40%
US Health Care
+0.75%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -0.08%  | +0.39% | +38.88%  | +43.33% | +18.60%  | -1.12% | +1.49% | +3.89% | |
| Flows |
Key fund info
Segment for quartile rank
Main characteristics
More details
NAV
6/11/2026
$61.70
1D NAV change
+2.77%
Dividend policy
Replication method
Indirect
Replication model
Unfunded swap
No. of holdings
255
Inception date
11/7/2014
Jurisdiction
Ireland
Distribution
Finland
Poland
Singapore (Qualified Investor)
Sweden
Portugal
Legal structure
Open-end Investment Company
Base currency
USD
Classification
Investment strategy
The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the performance of the NASDAQ Biotechnology Index, after fees. The index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market. Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The index is rebalanced quarterly and reviewed annually in December.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +0.39% | +38.88% | +43.33% | +18.60% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Exposure based on a proxy
More info
Countries
USA
91.12%
United Kingdom
1.93%
Bermuda
1.64%
Ireland
1.61%
Denmark
1.14%
Unavailable
0.12%
Other
2.44%
Sectors
Health Care
84.57%
Unavailable
15.41%
Diversification
Exposure based on a proxy
More info
Total weight of top 15 holdings out of 255
Top 15 holdings
Data as of April 30, 2026
Exposure based on a proxy
More info
Create a free account to view top holdings
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
1-year trailing difference
As of May 29, 2026
Create a free account to view the replication graph
SBIO
N/A
Replication quality
Calculated over 12m, as of May 29, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model
Issuer
Invesco
Invesco ID Card
Number of funds
645
Total AuM
€995.66B
Expense ratio range
0.04% - 5.39%
Average expense ratio
0.3514%
Top 5 funds by Invesco
| AuM | ||
|---|---|---|
QQQ | Invesco QQQ ETF | €412.37B |
QQQM | Invesco NASDAQ 100 ETF | €83.06B |
RSP | Invesco S&P 500® Equal Weight ETF | €79.06B |
SPXS | Invesco S&P 500 UCITS ETF | €34.22B |
SGLD | Invesco Physical Gold ETC | €22.65B |
Frequently asked questions about SBIO
What does Invesco NASDAQ Biotech UCITS ETF, SBIO, invest in?
SBIO is a Passive ETF. This ETF provides exposure to US Equities.
Which benchmark or index does SBIO replicate?
SBIO tracks the NASDAQ Biotechnology Total Return Index - USD, through a unfunded swap replication method.
What is the Total Expense ratio (TER) of SBIO?
SBIO carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.
When was SBIO launched?
SBIO was introduced to the market on November 7, 2014. It trades on Finland, among other exchanges
Who is the ETF issuer of SBIO?
Invesco NASDAQ Biotech UCITS ETF, SBIO, is provided by Invesco. Learn more about Invesco here.
What is the current assets under management (AUM) of SBIO?
SBIO oversees €358M in assets as of June 11, 2026.
How has SBIO performed lately?
Based on data from June 11, 2026, SBIO returned -0.08% over the past month, 0.39% over the last three months and 3.89% year-to-date.
What are the latest inflows or outflows for SBIO?
As of June 11, 2026, SBIO recorded net flows of +€12M over the last month and -€22M year-to-date.
Does SBIO distribute dividends?
SBIO follows a capitalizing, meaning it reinvests income within the fund.
What are the main country or region exposures of SBIO?
As of April 30, 2026, SBIO has significant geographic allocations in USA, United Kingdom and Bermuda.
In which sector or theme does SBIO invest in?
As of April 30, 2026, SBIO focuses largely on Health Care.
How many securities does SBIO hold and how diversified is it?
As of April 30, 2026, SBIO holds 255 positions in its portfolio, with 49.67% of assets concentrated in its top 15 holdings.
What are the main positions in SBIO?
As of April 30, 2026, SBIO top three holdings include AMGEN-T, GILEAD SCIENCES and VERTEX PHARMACEUTICALS.
What is the base currency of SBIO?
The base currency of SBIO is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
